Literature DB >> 6549010

Treatment of autochthonous rat colonic adenocarcinomas with a thioether-lysophospholipid derivative in mono- and combination chemotherapy.

M E Heim, M Swoboda, W Pahlke, L Edler, U Bicker.   

Abstract

In 361 Sprague-Dawley rats autochthonous colorectal carcinomas were induced by intrarectal application of the carcinogen AMMN. Tumor-bearing animals were treated with a synthetic thioether-lysophospholipid (TLP) derivative and in combination chemotherapy with 5-fluorouracil (5-FU) and carmustine (BCNU). There was no difference in the survival time of treated and untreated animals. The median large-bowel tumor weight was significantly lower in the TLP/5-FU and TLP/5-FU/BCNU combination therapy groups than in the control groups. Transient hepatotoxicity was observed in the high-dosage (50 mg/kg body weight twice weekly) TLP group. This study confirmed the relative resistance of AMMN-induced colorectal carcinomas to antineoplastic treatment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6549010     DOI: 10.1007/bf00390465

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  12 in total

1.  Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

Authors:  E J Freireich; E A Gehan; D P Rall; L H Schmidt; H E Skipper
Journal:  Cancer Chemother Rep       Date:  1966-05

Review 2.  Chemotherapy in alimentary tract malignomas.

Authors:  W Queisser; M E Heim
Journal:  Hepatogastroenterology       Date:  1981-10

3.  Survival and response to chemotherapy for advanced colorectal adenocarcinoma: an Eastern Cooperative Oncology Group report.

Authors:  P Lavin; A Mittelman; H Douglass; P Engstrom; D Klaassen
Journal:  Cancer       Date:  1980-10-01       Impact factor: 6.860

Review 4.  Anti-tumor action of alkyl-lysophospholipids (Review).

Authors:  W E Berdel; W R Bausert; U Fink; J Rastetter; P G Munder
Journal:  Anticancer Res       Date:  1981       Impact factor: 2.480

5.  Cytotoxicity of thioether-lysophospholipids in leukemias and tumors of human origin.

Authors:  W E Berdel; M Fromm; U Fink; W Pahlke; U Bicker; A Reichert; J Rastetter
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

6.  Studies on various parameters influencing leukemic cell destruction by alkyl-lysophospholipids.

Authors:  R Andreesen; M Modolell; G H Oepke; H Common; G W Löhr; P G Munder
Journal:  Anticancer Res       Date:  1982 Jan-Apr       Impact factor: 2.480

7.  Chemotherapy studies in autochthonous rat tumors intestinal cancer.

Authors:  F Sych; M Habs; D Schmähl
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1978-08-24

8.  Endoscopic diagnosis of chemically induced autochthonous colonic tumors in rats.

Authors:  R Merz; I Wagner; M Habs; D Schmähl; H Amberger; U Bachmann
Journal:  Hepatogastroenterology       Date:  1981-02

9.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1976-12       Impact factor: 7.640

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  2 in total

1.  Phase I trial of the thioether phospholipid analogue BM 41.440 in cancer patients.

Authors:  D B Herrmann; H A Neumann; W E Berdel; M E Heim; M Fromm; D Boerner; U Bicker
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

2.  In vitro and in vivo cytotoxicity of alkyl lysophospholipid ET-18-OCH3 and thioether lipid BM 41.440.

Authors:  G H Leder; H H Fiebig; E Wallbrecher; B R Winterhalter; G W Löhr
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.